- Home
- GIPR vs OGEN Comparison
GIPR vs OGEN Comparison
Compare GIPR & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIPR
- OGEN
- Stock Information
- Founded
- GIPR 2015
- OGEN 1996
- Country
- GIPR United States
- OGEN United States
- Employees
- GIPR N/A
- OGEN N/A
- Industry
- GIPR Real Estate Investment Trusts
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- GIPR Real Estate
- OGEN Health Care
- Exchange
- GIPR Nasdaq
- OGEN Nasdaq
- Market Cap
- GIPR 5.1M
- OGEN 5.0M
- IPO Year
- GIPR 2021
- OGEN N/A
- Fundamental
- Price
- GIPR $1.09
- OGEN $1.26
- Analyst Decision
- GIPR
- OGEN
- Analyst Count
- GIPR 0
- OGEN 0
- Target Price
- GIPR N/A
- OGEN N/A
- AVG Volume (30 Days)
- GIPR 569.9K
- OGEN 109.6K
- Earning Date
- GIPR 11-14-2025
- OGEN 11-12-2025
- Dividend Yield
- GIPR N/A
- OGEN N/A
- EPS Growth
- GIPR N/A
- OGEN N/A
- EPS
- GIPR N/A
- OGEN N/A
- Revenue
- GIPR $9,884,093.00
- OGEN N/A
- Revenue This Year
- GIPR $1.12
- OGEN N/A
- Revenue Next Year
- GIPR $0.52
- OGEN N/A
- P/E Ratio
- GIPR N/A
- OGEN N/A
- Revenue Growth
- GIPR 2.33
- OGEN N/A
- 52 Week Low
- GIPR $0.78
- OGEN $1.01
- 52 Week High
- GIPR $2.44
- OGEN $18.90
- Technical
- Relative Strength Index (RSI)
- GIPR 56.88
- OGEN 52.66
- Support Level
- GIPR $0.88
- OGEN $1.02
- Resistance Level
- GIPR $1.18
- OGEN $1.34
- Average True Range (ATR)
- GIPR 0.12
- OGEN 0.07
- MACD
- GIPR 0.03
- OGEN 0.05
- Stochastic Oscillator
- GIPR 33.87
- OGEN 75.76
About GIPR Generation Income Properties Inc.
Generation Income Properties Inc is an internally managed real estate investment company focused on acquiring and managing income-producing retail, office and industrial properties net leased to high-quality tenants in markets throughout the United States. Its key source of revenue is the rental income. The company holds properties in Alabama, Arizona, Colorado, the District of Columbia, Florida, Illinois, North Carolina and Virginia.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.